Pi­o­neer­ing re­gen­er­a­tive med sci­en­tist Lau­ra Nikla­son takes her com­pa­ny pub­lic in the lat­est big SPAC deal. And that gives her a shot at mak­ing biotech his­to­ry

Lau­ra Nikla­son left a promi­nent po­si­tion at Yale last fall so she could take charge of her re­gen­er­a­tive med biotech at a crit­i­cal point in its 17-year his­to­ry.

Cel­e­brat­ed by Time and For­tune, her­ald­ed as a leader in the long-run­ning re­gen­er­a­tive med tech­nol­o­gy sto­ry in tis­sue en­gi­neer­ing, with roots in the field that go back to her days as a post­doc in Bob Langer’s sto­ried lab at MIT, the sci­en­tif­ic founder of Hu­ma­cyte made a ca­reer switch that put her in charge of a com­pa­ny with 130 staffers and on­go­ing late-stage pro­grams that could put them on the thresh­old of com­mer­cial­iza­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER